# Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial

> **NCT02655536** · PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 109 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Brain Neoplasms

## Interventions

- **DRUG:** Bevacizumab plus erlotinib
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02655536
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-01
- **Primary completion:** 2019-06
- **Final completion:** 2019-12
- **Target enrollment:** 109 (ESTIMATED)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655536, "Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02655536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*